Sun, Dec 21, 2014, 10:17 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

GTX Inc. Message Board

  • science_editor84 science_editor84 Jan 10, 2013 11:30 AM Flag

    Next "diet" drug? GTXI = new muscle with no workouts

    "There may be a far better catalyst for this stock: GTx, Inc.'s enobosarm adds MUSCLE--not fat--to emaciated, deathly ill people, so what would it do for healthy and/or older people who want to add muscle?

    "That's the multibillion-dollar question I'd like analysts to ask GTX, Inc.'s CEO." (From comments section of Alpha article on GTXI http://seekingalpha.com/article/1101081-bullish-catalysts-make-gtx-top-biotech-buy-for-q1-2013?source=yahoo .)

    The GTXI article's author responded to that question:

    That is why Citi gave GTXI a $19/share price target. CEO Steiner tells us that GTx is in discussions with global pharmaceutical partners "right now." These companies want a piece of this huge and expanding indication pie for Enobosarm BEFORE the PDUFA. Very risky for an opportunistic, speculative biotech investor to be out of GTXI when global partnership deals are literally pending"

    NOTE: See also GTXI's November earnings report and more recent analyst presentation, which indicate GTXI's Enobosarm adding muscle--not fat--means it could be used not only for cancer patients but also for people with muscle-wasting diseases, the elderly, etc.

    More muscle burns more fat, so if approved by the FDA, Enobosarm has the potential to help obese people lose weight and help normal-weight folks add muscle and reduce flab.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GTXI
0.89-0.0800(-8.25%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.